Corteva (NASDAQ:CTVA) Coverage Initiated by Analysts at Monness Crespi & Hardt

Monness Crespi & Hardt started coverage on shares of Corteva (NASDAQ:CTVA) in a report released on Wednesday morning, BenzingaRatingsTable reports. The firm issued a sell rating and a $24.00 target price on the stock.

A number of other research analysts have also recently weighed in on CTVA. Deutsche Bank upgraded shares of Corteva from a hold rating to a buy rating and lifted their price objective for the company from $30.00 to $32.00 in a report on Sunday, June 16th. Goldman Sachs Group restated a buy rating on shares of WPP in a report on Monday, June 3rd. SunTrust Banks started coverage on shares of Corteva in a report on Monday, June 3rd. They issued a hold rating and a $29.00 price objective for the company. Sanford C. Bernstein started coverage on shares of Corteva in a report on Wednesday, June 5th. They issued a market perform rating and a $31.00 price objective for the company. Finally, Citigroup upgraded shares of Atara Biotherapeutics from a sell rating to a neutral rating and lifted their price objective for the company from $23.00 to $24.00 in a report on Monday, June 3rd. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and six have issued a buy rating to the company’s stock. Corteva presently has an average rating of Hold and an average target price of $30.79.

Shares of CTVA stock opened at $27.39 on Wednesday. The company has a 50 day simple moving average of $27.27. Corteva has a fifty-two week low of $24.35 and a fifty-two week high of $32.00.

The company also recently declared a quarterly dividend, which will be paid on Friday, September 13th. Shareholders of record on Wednesday, July 31st will be issued a dividend of $0.13 per share. This represents a $0.52 annualized dividend and a yield of 1.90%. The ex-dividend date is Tuesday, July 30th.

In other news, Director Gregory R. Page purchased 2,000 shares of the stock in a transaction on Monday, June 3rd. The stock was bought at an average price of $25.49 per share, for a total transaction of $50,980.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Salem Capital Management Inc. acquired a new position in Corteva during the 2nd quarter worth approximately $1,502,000. Bonness Enterprises Inc. purchased a new stake in shares of Corteva during the 2nd quarter worth approximately $724,000. Macnealy Hoover Investment Management Inc. purchased a new stake in shares of Corteva during the 2nd quarter worth approximately $227,000. Cardinal Capital Management purchased a new stake in shares of Corteva during the 2nd quarter worth approximately $709,000. Finally, Investors Research Corp purchased a new stake in shares of Corteva during the 2nd quarter worth approximately $73,000.

Featured Story: How to Profit and Limit Losses With Stop Orders

Analyst Recommendations for Corteva (NASDAQ:CTVA)

Receive News & Ratings for Corteva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corteva and related companies with MarketBeat.com's FREE daily email newsletter.